Brolucizumab Biosimilar, Anti-human VEGFA Monoclonal Antibody
$175.00 – $1,600.00
Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody. The research grade Brolucizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | C069P |
|---|---|
| Product Name | Brolucizumab Biosimilar, Anti-human VEGFA Monoclonal Antibody |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | VEGF, VEGF-A, vascular endothelial growth factor A |
| Summary | Recombinant Humanized IgG1 Monoclonal Antibody. |
| Source/Host | The anti-human vascular endothelial growth factor A (VEGF-A) monoclonal antibody brolucizumab biosimilar was produced in mammalian cells. |
| Specificity/Sensitivity | The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A). |
| Applications | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by brolucizumab. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | <1 EU/mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The research grade brolucizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | The research grade Brolucizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card. |
Description
C069P: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Background
Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab.
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.
Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Please remember our product information: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody: C069P Syd Labs
Additional information
| Size | 1 mg, 20 mg, 5 mg |
|---|